Arteriocyte to Accelerate Production of Nanofiber-Based Technology for Use in Clinical Research
Arteriocyte received a grant of $1 million from the Third Frontier Commission of the Ohio Department of Development to speed up manufacturing using Good Manufacturing practices (GMP), the company’s NANEX technology for clinical purposes under the brand HemaEx.
The NANEX technology is a three-dimensional nanofiber-based scaffold developed to imitate the bone marrow. It develops a quick ex vivo method to proliferate hematopoietic stem cells associated by least differentiation. This technology received license from John Hopkins University to improve stem cell treatments in order to cure cancer and cardiovascular diseases.
Arteriocyte introduced the technology commercially for research purposes in December 2010. This kit allows scientists to quickly expand HSCs to perform preclinical research. The company utilizes the grant to quickly upgrade its NANEX production plant to produce HemaEx culture ware which is "clinic-ready" and complies with GMP standards.
The company might work with the Ohio State University’s clinical partners to authenticate the use of HemaEx while conducting therapies to cure blood cancer. Arteriocyte is anticipated to continue its collaboration with Miltenyi Biotec to develop media additives that meets GMP standards and hence safe for human consumption. The company will soon release a GMP NANEX product for use in clinical research. It will also request regulatory approval to enable manufacturing of clinical cell therapy by 2013.
Please use one of the following formats to cite this article in your essay, paper or report:
APA
Chai, Cameron. (2019, February 12). Arteriocyte to Accelerate Production of Nanofiber-Based Technology for Use in Clinical Research. AZoNano. Retrieved on March 05, 2026 from https://www.azonano.com/news.aspx?newsID=23053.
MLA
Chai, Cameron. "Arteriocyte to Accelerate Production of Nanofiber-Based Technology for Use in Clinical Research". AZoNano. 05 March 2026. <https://www.azonano.com/news.aspx?newsID=23053>.
Chicago
Chai, Cameron. "Arteriocyte to Accelerate Production of Nanofiber-Based Technology for Use in Clinical Research". AZoNano. https://www.azonano.com/news.aspx?newsID=23053. (accessed March 05, 2026).
Harvard
Chai, Cameron. 2019. Arteriocyte to Accelerate Production of Nanofiber-Based Technology for Use in Clinical Research. AZoNano, viewed 05 March 2026, https://www.azonano.com/news.aspx?newsID=23053.
We're committed to providing free access to quality science. By registering and providing insight into
your preferences you're joining a community of over 1m science interested individuals and help us to
provide you with insightful content whilst keeping our service free.
or
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.